Effects of chronic systemic treatment with peroxisome proliferator-activated receptor α activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice

Neuroscience Research

Volumn 70, Issue 2, 2011, Pages 230-237

  Wang, Guangming ^a   Namura, Shobu ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Adhesion molecule; Cytokine; Fibrate; Innate immune response; Lipopolysaccharide; Microglia; PPAR; Stroke

Indexed keywords

BRAIN PROTEIN; CD31 ANTIGEN; CYCLOOXYGENASE 2; FENOFIBRATE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; PIRINIXIC ACID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CELL ACTIVATION; CONTROLLED STUDY; ENCEPHALITIS; HISTOPATHOLOGY; MACROPHAGE; MALE; MICROGLIA; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOMATOSENSORY CORTEX;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; DISEASE MODELS, ANIMAL; FENOFIBRATE; FIBRIC ACIDS; INFLAMMATION MEDIATORS; INJECTIONS, INTRAVENTRICULAR; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; PPAR ALPHA; PYRIMIDINES;

EID: 79955667671     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2011.02.001     Document Type: Article

References (31)

1. Bright J.J., Kanakasabai S., Chearwae W., Chakraborty S. PPAR regulation of inflammatory signaling in CNS diseases. PPAR Res. 2008, 2008:658520.
2. Chinetti G., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 2000, 49:497-505.
3. Collino M., Aragno M., Mastrocola R., Benetti E., Gallicchio M., Dianzani C., Danni O., Thiemermann C., Fantozzi R. Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic. Biol. Med. 2006, 41:579-589.
4. Cunard R., DiCampli D., Archer D.C., Stevenson J.L., Ricote M., Glass C.K., Kelly C.J. WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J. Immunol. 2002, 169:6806-6812.
5. Daynes R.A., Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2002, 2:748-759.
6. Deplanque D., Gele P., Petrault O., Six I., Furman C., Bouly M., Nion S., Dupuis B., Leys D., Fruchart J.C., Cecchelli R., Staels B., Duriez P., Bordet R. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. 2003, 23:6264-6271.
7. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., Wahli W. The PPARα-leukotriene B4 pathway to inflammation control. Nature 1996, 384:39-43.
8. Drew P.D., Xu J., Storer P.D., Chavis J.A., Racke M.K. Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem. Int. 2006, 49:183-189.
9. Glass C.K., Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol. 2010, 10:365-376.
10. Gocke A.R., Hussain R.Z., Yang Y., Peng H., Weiner J., Ben L.H., Drew P.D., Stuve O., Lovett-Racke A.E., Racke M.K. Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-α agonists in autoimmune disease. J. Immunol. 2009, 182:4479-4487.
11. Guo Q., Wang G., Liu X., Namura S. Effects of gemfibrozil on outcome after permanent middle cerebral artery occlusion in mice. Brain Res. 2009, 1279:121-130.
12. Guo Q., Wang G., Namura S. Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice. J. Cereb. Blood Flow Metab. 2010, 30:70-78.
13. Heneka M.T., Landreth G.E. PPARs in the brain. Biochim. Biophys. Acta 2007, 1771:1031-1045.
14. Inoue H., Jiang X.F., Katayama T., Osada S., Umesono K., Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci. Lett. 2003, 352:203-206.
15. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and disease. Nature 2000, 405:421-424.
16. Kono K., Kamijo Y., Hora K., Takahashi K., Higuchi M., Kiyosawa K., Shigematsu H., Gonzalez F.J., Aoyama T. PPARα attenuates the proinflammatory response in activated mesangial cells. Am. J. Physiol. Renal Physiol. 2009, 296:F328-F336.
17. Lee J.H., Joe E.H., Jou I. PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharide-activated rat glia. Neuroreport 2005, 16:829-833.
18. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
19. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., Racke M.K. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol. 2004, 172:5790-5798.
20. Offner H., Subramanian S., Parker S.M., Wang C., Afentoulis M.E., Lewis A., Vandenbark A.A., Hurn P.D. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J. Immunol. 2006, 176:6523-6531.
21. Offner H., Subramanian S., Parker S.M., Afentoulis M.E., Vandenbark A.A., Hurn P.D. Experimental stroke induces massive, rapid activation of the peripheral immune system. J. Cereb. Blood Flow Metab. 2008, 26:654-665.
22. Okamoto H., Iwamoto T., Kotake S., Momohara S., Yamanaka H., Kamatani N. Inhibition of NF-kappa B signaling by fenofibrate, a peroxisome proliferator activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin. Exp. Rheumatol. 2005, 23:323-330.
23. Ouk T., Laprais M., Bastide M., Mostafa K., Gautier S., Bordet R. Withdrawal of fenofibrate treatment partially abrogates preventive neuroprotection in stroke via loss of vascular protection. Vascul. Pharmacol. 2009, 51:323-330.
24. Paintlia M.K., Paintlia A.S., Contreras M.A., Singh I., Singh A.K. Lipopolysaccharide-induced peroxisomal dysfunction exacerbates cerebral white matter injury: attenuation by N-acetyl cysteine. Exp. Neurol. 2008, 210:560-576.
25. Paintlia M.K., Paintlia A.S., Khan M., Singh I., Singh A.K. Modulation of peroxisome proliferator-activated receptor-alpha activity by N-acetyl cysteine attenuates inhibition of oligodendrocyte development in lipopolysaccharide stimulated mixed glial cultures. J. Neurochem. 2008, 105:956-970.
26. Rivest S. Regulation of innate immune responses in the brain. Nat. Rev. Immunol. 2009, 9:429-439.
27. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393:790-793.
28. Tanaka T., Kohno H., Yoshitani S., Okumura A., Murakami A., Hosokawa M. Ligands for peroxisome proliferator activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. 2001, 61:2424-2428.
29. Xu J., Storer P.D., Chavis J.A., Racke M.K., Drew P.D. Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J. Neurosci. Res. 2005, 81:403-411.
30. Xu J., Chavis J.A., Racke M.K., Drew P.D. Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J. Neuroimmunol. 2006, 176:95-105.
31. Xu J., Racke M.K., Drew P.D. Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis. J. Neurochem. 2007, 103:1801-1810.